Over the last few years, Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and liraglutide, have emerged as alternatives to surgery to achieve effective weight loss in patients living with obesity. The gene discussed is GLP1R; the disease is Obesity.